Articles that tag CADL but are mainly about other companies.
Lead candidate aglatimagene completed pivotal phase III study with positive results showing 39% improvement in prostate cancer-specific disease-free survival. FDA filing planned for Q4 2026 with Fast Track and Regenerative Medicine Advanced Therapy designations supporting regulatory review. Key near-term catalyst.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
